[Efficacy and safety of JAK inhibitor ruxolitinib in Chinese patients with myelofibrosis: results of a 1-year follow-up of A2202].

ABSTRACT: Objective: To evaluate the efficacy and safety of ruxolitinib in Chinese myelofibrosis patients. Methods: This study enrolled 63 Chinese patients(32 males and 31 females)in total, whose median age was 55(25-79)years. The initial dose of ruxolitinib was 30mg/d(25 patients)with a baseline of PLT(100-200)×10⁹/L and 40 mg/d(38 patients)with a baseline of PLT>200×10⁹/L. Spleen volume, quality of life(QOL)and symptoms were evaluated by MRI/CT, European Organization for Research and Treatment of Cancer QOL Questionnaire Core 30(EORTC QLQ-C30)and MF Symptom Assessment Form(MFSAF)v2.0 questionnaire. Results: At the time of this analysis(follow-up of 12 months), 47 patients(74.6%)were still receiving treatment, 25 patients(39.7%)achieved ≥35% reduction in s

SUBMITTER: Jin J 

PROVIDER: S-EPMC7364878 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature